Core Viewpoint - Watson Bio continues to strengthen its core competitiveness and cultivate new growth momentum in the vaccine industry despite common development challenges, achieving approximately 1.154 billion yuan in revenue and a net profit of about 43.16 million yuan in the first half of 2025 [1] Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of approximately 1.154 billion yuan and a net profit attributable to shareholders of approximately 43.16 million yuan [1] - The company plans to distribute cash dividends of 0.30 yuan per 10 shares, amounting to an estimated total payout of about 47.98 million yuan, reflecting strong cash reserves and a commitment to shareholder returns [5] Group 2: International Expansion - In the first half of 2025, Watson Bio's overseas business revenue reached 214 million yuan, with new export markets including Ghana and Myanmar, expanding its international market presence [2] - The company has exported over 63 million doses of its products to 24 countries and regions, maintaining a leading position among domestic vaccine companies in terms of export volume (excluding COVID-19 vaccines) [2] Group 3: Strategic Initiatives - Watson Bio has entered the micro-ecological health and functional nutrition intervention fields, signing exclusive licensing agreements to develop and commercialize core microbiome technologies in mainland China, Hong Kong, and Macau [3] - The company is establishing a synthetic biology platform in collaboration with local universities and research institutions, focusing on the industrialization of natural products and functional proteins [4] Group 4: Social Responsibility - In the first half of 2025, the company donated over 3,000 doses of bivalent HPV vaccines, demonstrating its commitment to social responsibility and women's health [5] - The company emphasizes the importance of fulfilling social responsibilities while pursuing business development, aiming for high-quality and sustainable growth [6]
沃森生物2025半年报:疫苗海外发力,布局微生态与合成生物